Short Interest in Apollomics, Inc. (NASDAQ:APLMW) Drops By 17.2%

Apollomics, Inc. (NASDAQ:APLMW) was the target of a large decline in short interest in October. As of October 31st, there was short interest totalling 53,800 shares, a decline of 17.2% from the October 15th total of 65,000 shares. Based on an average trading volume of 22,000 shares, the days-to-cover ratio is currently 2.4 days.

Apollomics Price Performance

Shares of NASDAQ APLMW opened at $0.01 on Friday. Apollomics has a 1-year low of $0.01 and a 1-year high of $0.06. The business has a 50-day moving average of $0.01 and a 200-day moving average of $0.01.

Apollomics Company Profile

Apollomics, Inc, a biotechnology company, engages in the discovery and development of mono and combination oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. Its pipeline consists of various development-stage assets, including novel and humanized monoclonal antibodies that restore the body's immune system to recognize and kill cancer cells, and targeted therapies against uncontrolled growth signaling pathways.